MPH (MPH) News
Follow MPH (MPH) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Medicure Inc. (MPH) Completes Enrollment in Phase 3 PNPO Trial
Medicure completed enrollment of 10 patients in its MEND-PNPO Phase 3 study of MC-1 for PNPO deficiency. The program has FDA Orphan, Rare Pediatric Disease, and Fast Track designations; MC-1 is not FDA-approved.Material
REGULATION | Sep 28, 2026, 10:01 PM UTC
L
Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial
WINNIPEG, MB / / September 28, 2026 / Medicure Inc. ("Medicure" or the "Company") TSXV:MPHOTC:MCUJF, a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and
NEWS | Sep 28, 2026, 10:01 PM UTC
L
Medicure shares MEND-PNPO Phase 3 design and baseline data at congress
Medicure announced its MEND-PNPO Phase 3 study design and baseline data at the 16th European Epilepsy Congress.
GEOPOLITICS | Sep 08, 2026, 10:25 PM UTC
L
Medicure Announces CFO Change
WINNIPEG, MB / / July 3, 2026 / Medicure Inc. ("Medicure" or the "Company") (T
EQUITY | Jul 03, 2026, 09:02 PM UTC